Wedbush Starts Autodesk (ADSK) at Neutral, Saying Cyclical Issues Could Persist
Tweet
Share
E-mailGet Alerts ADSK Hot Sheet
Price: $251.66 -2.44%
Rating Summary:
36 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
36 Buy, 9 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush initiates coverage on Autodesk (NASDAQ: ADSK) with a Neutral rating and $36 price target.
The analyst comments, "ADSK benefits from global development trends and a strong market position, with the largest worldwide channel network of any design software vendor. Due to the company’s exposure to the credit-sensitive small and mid-sized business (SMB) sector, ADSK shares are generally discounted relative to their long-term growth potential. At present, shares are trading at the largest discount to the median software forward P/E since late 2008 during the height of the recession."
For an analyst ratings summary and ratings history on Autodesk click here. For more ratings news on Autodesk click here.
Shares of Autodesk closed at $32.74 yesterday.
The analyst comments, "ADSK benefits from global development trends and a strong market position, with the largest worldwide channel network of any design software vendor. Due to the company’s exposure to the credit-sensitive small and mid-sized business (SMB) sector, ADSK shares are generally discounted relative to their long-term growth potential. At present, shares are trading at the largest discount to the median software forward P/E since late 2008 during the height of the recession."
For an analyst ratings summary and ratings history on Autodesk click here. For more ratings news on Autodesk click here.
Shares of Autodesk closed at $32.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
- Citi Starts Luxshare Precision (2475:HK) at Buy
- Leerink Starts Ligand Pharma (LGND) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
